

CTT Systems

Waiting on the world to change

- External headwinds delay earnings recovery until 2026e
- '25e-'27e EBIT down 27-3%; 18% EBIT CAGR '24-'27e
- 19-13x EBIT '26e-'27e, ~40-50% ROCE, net cash

2025 to be a challenging year...

The fact that the aerospace industry is gradually getting its supply chain in order, and that OEMs are now clearly increasing production rates, unfortunately had little impact on CTT's near-term earnings. Q3 sales was roughly in the middle of CTT's own guidance, but we fear that CTT will see fairly stable sales into Q4 due to FX headwinds and inventory destocking. What is clear, however, is the strong growth potential going into 2026 – something that was also emphasised by management during the conference call. Starting in Q1'26, we expect normalised inventory levels among distributors, increased production rates, normalised lead times and higher content per aircraft to allow CTT to almost double system sales vs. 2024 and grow by ~50-30% in 2027e-28e. In addition, the installed base continued to grow in 2025, which should support >20% growth in aftermarket sales during '26e. With growth turning positive again, we expect the scalability of the business model to allow CTT to offset FX headwinds and return to >30% EBIT margins (19% '25e).

...but increased confidence in 2026 recovery

We lower '25e EBIT by 27% due to lower AM sales and FX, and '26e-'27e EBIT by 3%. From 2026e, the combination of accelerated OEM sales, increased customer wins within both VIP and retrofits, and a recovering aftermarket business should drive ~50-40% organic sales growth and ~130-50% EBIT growth (18% adj. EBIT CAGR '24-'27e).

Multi-year double-digit growth potential

The core strengths of CTT remain: the company benefits from a near-monopolistic market position, strong demand, and its margin-accretive AM business. This should drive long-term double-digit earnings growth, while the share is now trading at 43/19/13x EBIT '25e-'27e (22x L10Y), offers 3-6% dividend yields '25e-'27e (>90% payout), and ~20-50% ROCE.

Analyst(s): karl.bokvist@abgsc.se, +46 8 566 286 33
 adrian.gilani@abgsc.se, +46 8 566 286 92

SEKm	2023	2024	2025e	2026e	2027e
Sales	309	300	285	427	583
EBITA adj.	121	112	55	126	186
EBITA adj. marg. (%)	39.3	37.5	19.5	29.5	31.9
EBIT adj.	121	112	55	126	186
EBIT adj. marg. (%)	39.3	37.5	19.5	29.5	31.9
Pretax profit	120	108	55	130	191
EPS	7.62	6.81	3.50	8.25	12.08
EPS adj.	7.81	6.81	3.63	8.25	12.08
Sales growth (%)	28.3	-2.8	-5.1	50.0	36.4
EPS adj. growth (%)	47.4	-12.8	-46.7	127.3	46.4
DPS	8.70	5.35	6.00	9.00	12.00

Source: ABG Sundal Collier, Company Data

Reason: Post-results comment

Commissioned research

Not rated

Capital Goods

Estimate changes (%)

	2025e	2026e	2027e
Sales	-5.2	-1.3	-1.9
EBIT	-26.7	-3.2	-3.4
EPS	-27.3	-3.1	-3.3

Source: ABG Sundal Collier


CTT-SE/CTT SS

Share price (SEK) 24/10/2025 193.00

MCap (SEKm)	2,418
MCap (EURm)	221
No. of shares (m)	12.5
Free float (%)	74.5
Av. daily volume (k)	11

Next event Q4 Report 6 February 2026

Performance



	2025e	2026e	2027e
P/E (x)	55.1	23.4	16.0
P/E adj. (x)	53.2	23.4	16.0
EV/EBIT (x)	44.8	18.9	12.8
EV/EBIT adj. (x)	43.2	18.9	12.8
EV/EBITA adj. (x)	43.2	18.9	12.8
EV/sales (x)	8.41	5.58	4.09
Le. adj. FCF yld. (%)	2.5	3.6	4.7
Dividend yield (%)	3.1	4.7	6.2
ROCE adj. (%)	17.3	40.1	54.4
ROE adj. (%)	16.3	36.7	48.1
Net IB debt/EBITDA (x)	-0.4	-0.2	-0.2
Le. adj. ND/EBITDA (x)	-0.4	-0.2	-0.2

Disclosures and analyst certifications are located on pages 17-18 of this report.


This research product is commissioned and paid for by the company covered in this report. As such, this report is deemed to constitute an acceptable minor non-monetary benefit (i.e. not investment research) as defined in MiFID II.

Company description

CTT Systems develops climate control products for aircraft, including dehumidification systems to prevent condensation and humidifiers for crew and passenger wellbeing. CTT's products are offered on the Boeing 787 and 777X as well as the Airbus A380 and A350. The company holds a majority market share within both dehumidification and humidification products and is a tier-1 supplier to the Boeing 787 and 777X.


[Sustainability information](#)

Sales, margins and AM share




Source: ABG Sundal Collier, company data

Sales split by customer (%)



Source: ABG Sundal Collier, company data

Sales split by region (%)




Source: ABG Sundal Collier, company data

Risks


The high profitability in CTT's systems could attract new competitors, or result in the OEM suppliers providing their own solutions. While CTT's relationships with Airbus and Boeing are highly valuable, they have little influence over pricing and therefore are sensitive to contract renegotiations. Almost all revenues are dollar-based, implying a strong currency sensitivity. The main risks entail a lack of market penetration due to low willingness among airlines to have dehumidifiers and humidifiers installed.

R12m sales by segment




Source: ABG Sundal Collier, company data

Sales split by end-customer, 2021



Source: ABG Sundal Collier, company data

Valuation and profitability



Source: ABG Sundal Collier, company data

Outcome vs. expectations

Deviation table SEKm	Q3'24	Q3'25 Actual	y-o-y %	Q3'25e ABGSCe	Deviation SEKm	%
Net sales	57.4	73.8	29%	77.6	-3.8	-5%
Other income	-1.5	6.1		6.2		
Opex	-39.2	-59.7	52%	-57.0	-2.7	5%
EBITDA	16.7	20.2	21%	26.8	-6.6	-25%
D&A	-1.9	-1.6		-1.7		
EBIT	14.8	18.6	26%	25.1	-6.5	-26%
Non-recurring items	0.0			0.0		
Adj. EBIT	14.8	18.6	26%	25.1	-6.5	-26%
Net profit	12.0	14.4	20%	20.6	-6.2	-30%
Assumptions	Q3'24	Q3'25 Actual	y-o-y %	Q3'25e ABGSCe	Deviation SEKm	%
Opex / sales	68%	81%		73%		7%
EBIT margin	26%	27%		32%		-5%
Adj. EBIT margin	26%	25%		32%		-7%
Organic sales	-18%	39%		42%		-3%
Sales y-o-y	-22%	29%		35%		
Adj. EBIT y-o-y	-51%	29%		70%		
Sales breakdown	Q3'24	Q3'25 Actual	y-o-y %	Q3'25e ABGSCe	Deviation SEKm	%
OEM	10.3	11.9	16%	10.1	1.8	18%
Retrofits	0.0	2.5	n.a.	4.5	-2.0	-44%
VIP	1.2	13.2	1000%	8.9	4.3	48%
Other	2.5	2.6	4%	3.0	-0.4	-13%
System sales	14.0	30.2	116%	26.5	3.7	14%
Aftermarket / IP	43.4	43.6	0%	51.1	-7.5	-15%
Group sales	57.4	73.8	29%	77.6	-3.8	-5%
AM+IP/sales	76%	59%		66%		-7%

Source: ABG Sundal Collier, company data

Estimate changes


Estimate changes SEKm	Old forecast			New forecast			Estimate changes Δ			Estimate changes %		
	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e
Net sales	300	433	594	285	427	583	-16	-6	-11	-5%	-1%	-2%
Other income	24	23	22	25	24	22	0	2	0	1%	7%	0%
Opex	-245	-318	-413	-249	-318	-408	-4	0	5	2%	0%	-1%
EBITDA	80	138	203	60	134	197	-20	-4	-6	-25%	-3%	-3%
D&A	-7	-8	-11	-7	-8	-11	0	0	0	-3%	0%	0%
EBIT	73	130	192	53	126	186	-19	-4	-6	-27%	-3%	-3%
Non-recurring items	-2	0	0	-2	0	0	0	0	0	0%	n.a.	n.a.
Adj. EBIT	75	130	192	55	126	186	-19	-4	-6	-26%	-3%	-3%
Net profit	60	107	157	44	103	151	-16	-3	-5	-27%	-3%	-3%
Assumptions	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e
EBIT margin	24%	30%	32%	19%	30%	32%				-5.5%	-0.6%	-0.5%
Adj. EBIT margin	25%	30%	32%	19%	30%	32%				-5.5%	-0.6%	-0.5%
EBIT y-o-y	-35%	79%	47%	-52%	136%	47%						
Adj. EBIT y-o-y	-33%	74%	47%	-51%	128%	47%						
Organic sales	7%	47%	37%	3%	54%	36%						
FX	-7%	-3%	0%	-8%	-4%	0%						
Sales y-o-y	0%	44%	37%	-5%	50%	36%						
Sales breakdown	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e
OEM	56	129	201	56	130	201	1	1	1	1%	0%	0%
Retrofits	5	10	12	6	12	14	1	2	2	22%	16%	16%
VIP	29	52	78	34	55	80	5	3	2	17%	6%	2%
Other	13	13	13	13	13	13	0	0	0	-3%	-3%	-3%
System sales	103	205	304	109	209	308	6	5	4	6%	2%	1%
Aftermarket / IP	198	228	290	176	218	275	-22	-11	-16	-11%	-5%	-5%
Group sales	300	433	594	285	427	583	-16	-6	-11	-5%	-1%	-2%
AM+IP/sales	66%	53%	49%	62%	51%	47%				-4.0%	-1.8%	-1.7%

Source: ABG Sundal Collier, company data

Air travel historically resilient in economic downturns


We believe that the first summer following the pandemic led to a surge in leisure travel. Although a weaker economic climate could adversely impact the ongoing air travel recovery, we note that multiple Western airlines (Delta, United, Ryanair, Lufthansa, SAS, Norwegian, etc) saw continued high air travel activity and a good level of bookings well in 2023-2024. Historically, we note that air travel has been resilient during economic downturns (down to the low-single digits in 1980, 2001, 2002 and 2008) and that Airbus expects global air travel to surpass 2019 levels in 2024. As shown below, the world seems to be on track to achieve this level of air traffic. This in turn should support continued system sales for CTT once the supply chain issues subside.

Passenger travel worldwide (mn), 1979-2019



Source: ABG Sundal Collier, IATA

Airbus 2024 global market forecast




Source: ABG Sundal Collier, Airbus

Flight traffic now above pre-pandemic levels

As shown below, CTT's share price correlated well with the ongoing recovery in commercial air traffic. In the near term, we note that commercial air travel (according to Flightradar) has continued to improve and is now ~25% above 2019 levels.

Commercial flight traffic globally



Source: ABG Sundal Collier, Flightradar24

CTT's share price vs. flight traffic data




Source: ABG Sundal Collier, Flightradar24, FactSet

Underlying flight travel supports growing aftermarket


Since the start of 2020, CTT's share price is up 4%, while flight travel is up 25%. The more important aspect from a fundamental point of view is the effect that flight travel should have on CTT's earnings. First, higher air travel demand raised demand for more aircraft. This in turn leads to higher system sales. As these systems run onboard active aircraft, it drives aftermarket sales. Thus, as air travel continues to grow, so should aftermarket sales as it drives an underlying need to replace consumables and spare parts for CTT's installed base. As of Q3'25, we estimate that CTT's aftermarket revenues have grown by 10% p.a. organically since 2020, which can be compared to the 7% annualised growth in flight travel.

CTT's share price vs. flight traffic, indexed



Source: ABG Sundal Collier, Flightradar24, FactSet

Indexed flight travel vs. CTT's AM sales




Source: ABG Sundal Collier, company data, Flightradar24

Long-term outlook remains solid

Despite the ongoing challenges following the pandemic, and the current supply chain and quality issues negatively affecting build rates at Boeing and Airbus, the order books are stronger than ever. In Airbus' latest Global Market Forecast, world air traffic is expected to grow by ~8% p.a. until 2027, and by ~4% thereafter, while the total base of widebody deliveries is expected to double between 2023 and 2043. This implies ~8k new deliveries (mainly B787, A350, B777X, all key platforms for CTT), which can be compared to the ~1.7k B787 and A350 delivered during 2011-2023. Thus, we continue to believe that CTT's underlying market exposure is highly attractive, and that visibility remains high.

Passenger forecast: 8.4% CAGR '23-'27, 3.6% '27-'43


World air traffic (trillion RPK)*



Source: ABG Sundal Collier, Airbus

Widebody forecast: 3% CAGR '23-'43, ~8k new aircraft

Number of aircraft



Source: ABG Sundal Collier, Airbus


Delayed ramp up among OEMs now happening

One of the key drivers of CTT's OEM revenues is the monthly production at Boeing (B787, B777X, bizjets) and Airbus (A350, bizjets). Production rates were consistently lowered during the pandemic but are now starting to show the opposite trend, with the pandemic-era cash-preservation trend turning into an immense focus on ramping up production as quickly as possible. This ramp-up has faced several obstacles, including internal challenges within Boeing (quality issues, legal challenges, management replacements) but also broader supply chain challenges (shortage of supply from players such as Spirit, and prolonged approval processes for cabin interior) that has affected both Boeing and Airbus. Thus, the actual monthly delivery rate has been at roughly 6 for Airbus A350, while Boeing's delivery rate has picked up from 0 in mid-2022 to ~7 in June '25.

For Boeing, the end-of-quarter production rate of the B787 in Q2'25 was at 7 per month, with a target to reach 7 in 2025 and 10 in 2026. On the long-range B777X, numerous delays now mean that the first commercial deliveries will be in 2026, but CTT has already started to ship small amounts of humidifiers to this platform. We find it positive to see that the long-haul market is gradually improving (from low levels), and view CTT's position as strong given that the B777X will essentially be the only remaining 'true' long-haul aircraft following the retirement of the B747 and A380 programmes. Prior to the pandemic, Boeing produced roughly 100 'older version' B777s p.a. In addition, Boeing recently halted its flight testing, which means that sales from CTT will likely take place first in late 2025.


When it comes to Airbus, the company expects to see the commercial aircraft market return to pre-pandemic levels in 2025, led by the narrow-body segment. For CTT, Airbus is currently producing 6 A350 aircraft per month and aims to raise this level to roughly 10 aircraft p.a. in 2026, and 12 p.a. in 2028. However, the ongoing supply chain challenges means that the production rate of 10 will likely be reached towards the end of 2026, or in 2027. In addition, we found it positive to hear from CTT that penetration among new airlines continues to improve (similar penetration in the cockpit as on the B787, rising in the flight deck, promising in the business/premium cabin), as well as the disclosed selection from Air India (2 humidifiers per aircraft) and that, in Q3, another (undisclosed) airline had selected full penetration (three cabin zones, flight deck and crew rest) for the A350s that are set to be delivered from 2025.

Monthly deliveries



Source: ABG Sundal Collier, company data


Monthly delivery rate, R12m



Source: ABG Sundal Collier, company data


We have assumed that long-haul production rates (B787, A350, B777X) will approach pre-COVID-19 levels in 2026, and for deliveries to surpass 2019 levels in 2027. However, CTT sales will diverge from production rates, as OEMs are struggling with supply constraints. This should normalise during 2025, according to CTT's management. In addition, we expect the combination of rising production rates as well as higher content per aircraft to have a clear benefit on CTT's OEM sales already from Q1'26.

B787/A350 deliveries vs. CTT's OEM sales



Source: ABG Sundal Collier, company data

Long-haul delivery assumptions (# of aircraft)




Source: ABG Sundal Collier, company data

Aftermarket surpassed 2019 levels in 2022


CTT's aftermarket sales correlate closely with the number of hours flown by its installed population. Naturally, the sharp decline in flight hours due to the pandemic had an immediate impact on CTT's business. However, the strength of CTT's aircraft exposure, as highlighted earlier, is that the fleet is relatively modern and has therefore been used to a far higher extent than older aircraft models due to their superior economics. Thus, CTT claims that 90-100% of its installed population is currently back in service. As air traffic continues to grow, we expect the ongoing recovery in CTT's aftermarket sales to continue as well, despite the Q3'24, Q1'25 and Q4'25 inventory correction among distributors, and expect 5-10% in the installed base 2025, before reaching ~20% in 2026.

CTT's installed base (units): 15% CAGR



Source: ABG Sundal Collier, company data


CTT's AM sales vs. B787 aircraft in-service



Source: ABG Sundal Collier, company data


As seen in 2024, CTT's aftermarket sales were ~50% above their 2019 levels, but this was not only due to recovering air traffic. First, we note that CTT's installed base continued to grow in 2020-2022, implying a larger underlying sales base than the company had in 2019. In addition, we believe that pricing (and FX) has supported growth by at least 5-10% vs. 2019 levels. As shown below, CTT's installed base grew by 20% p.a. in 2015-2019 whereas its aftermarket sales had an organic sales CAGR of 38%. We expect CTT's aftermarket sales to continue to outgrow the underlying installed base for the aforementioned reasons, and to reach sales of ~SEK 360m in 2029e, while inventory corrections should only have a short-term impact on sales.

CTT's installed base vs. AM sales



Source: ABG Sundal Collier, company data

Indexed installed base vs. CTT's org AM sales



Source: ABG Sundal Collier, company data

Aftermarket to account for ~90-70% of '26e-'29e EBIT

We believe that the impressive strength in CTT's profitable aftermarket-based business model should continue to drive sales growth despite the slowdown in OEM sales during the pandemic. For '19-'25e, we forecast a -4% sales CAGR, as growth in the installed base and positive pricing has been held back by low system sales. This in combination with the emerging private jet potential are the primary drivers behind our -4% estimated organic sales CAGR for '19-'25e, which should accelerate to a 29% CAGR '24-'27e (9% '19-'29e) as system sales accelerate.

CTT's aftermarket primarily concerns consumables, and we estimate this sales channel to have margins just above 50%. The non-AM part of CTT has therefore been running at a loss in 2020-2025e, which we find reasonable given the drop in sales, the higher cost base and the lower pricing potential. As such, we expect CTT to deliver >30% EBIT margins from 2022 (thanks to accretive AM/VIP sales), and that the company will achieve a -11% adj. EBIT CAGR for '19-'25e, but an 18% CAGR '24-'27e (9% '19-'29e). Even as OEM sales begin to normalise and VIP sales start to take off, we expect the aftermarket to account for 92-78% of EBIT in 2026e-2027e. Finally, CTT's asset-light business model means that the company is already running at net cash as of 2022, and ~40-50% future ROIC.

Earnings forecast

Earnings forecast	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	'19-'25e	'19-'29e	'24-'27e
OEM	167	83	25	20	36	40	56	130	201	252	269	-17%	5%	71%
Aftermarket	147	72	99	187	243	233	176	218	275	316	363	3%	9%	6%
VIP	15	32	10	21	18	14	34	55	80	124	142	15%	25%	77%
Retrofit/other	27	14	18	13	13	12	18	24	27	31	37	-6%	3%	31%
Group sales	355	201	151	241	309	300	285	427	583	722	812	-4%	9%	25%
y-o-y	13%	-43%	-25%	59%	28%	-3%	-5%	50%	36%	24%	12%			
Organic	7%	-42%	-19%	36%	23%	-2%	3%	54%	36%	24%	12%	-4%	9%	29%
Sales split (%)														
OEM	47%	41%	16%	8%	11%	13%	20%	30%	35%	35%	33%			
Aftermarket	41%	36%	65%	78%	79%	78%	62%	51%	47%	44%	45%			
VIP	4%	16%	6%	9%	6%	5%	12%	13%	14%	17%	18%			
Retrofit/other	8%	7%	12%	5%	4%	4%	6%	6%	5%	4%	5%			
EBIT	120	38	27	92	118	112	53	126	186	236	269	-13%	8%	18%
Non-recurring items	7	7	5	0	-3	0	-2	0	0	0	0			
Adj. EBIT	113	32	22	92	121	112	55	126	186	236	269	-11%	9%	18%
Margin	32%	16%	14%	38%	39%	37%	19%	30%	32%	33%	33%			
y-o-y	22%	-72%	-31%	318%	32%	-7%	-51%	128%	47%	27%	14%			
ABGSCe margin, AM	48%	50%	50%	50%	50%	50%	53%	53%	53%	53%	53%			
AM share of EBIT	63%	113%	225%	102%	100%	104%	168%	92%	78%	71%	72%			
ABGSCe margin, non-AM	20%	-3%	-52%	-3%	0%	-6%	-35%	5%	13%	17%	17%			
Net debt	-78	15	23	-15	-76	-25	-22	-33	-34	-42	-42			
FCF	86	-44	22	54	109	62	60	86	113	158	189			
FCF conversion (FCF / EBIT)	72%	#####	81%	59%	92%	55%	112%	68%	61%	67%	70%			
Dividends	-51	-51	-22	-10	-51	-109	-67	-75	-113	-150	-188			
% of EBIT -1y	56%	42%	57%	37%	55%	92%	60%	141%	89%	81%	79%			
ROIC	55%	13%	7%	30%	39%	35%	17%	40%	52%	59%	61%			

Source: ABG Sundal Collier, company data

Possibility to achieve up to ~25% annual return until 2029

Looking into 2029, we expect CTT to generate sales of SEK 812m, EBIT of SEK 269m (33% margin) and FCF of SEK 189m, while yielding a ROIC of ~60%. Thus, we believe that the return in air traffic should support a return to form for CTT's impressive, asset-light business. Based on the current share price of SEK 193 (SEK 2.4bn market cap), this would yield an implicit 2027e-2029e EV/EBIT of 13-9x (17-13x if we only include the earnings from the 50% + margin aftermarket business), and 5-8% FCF yields. Historically, we note that CTT's five-year average F12m EV/EBIT (FactSet) has been ~23x.

Taking a different perspective, we aim to illustrate the potential annual shareholder return (including dividends) that one would receive assuming varying EV/EBIT multiples on CTT's 2029e earnings. As shown below, valuing CTT at 20x '29e EV/EBIT would mean a dividend-adjusted market cap of SEK 5.9bn, implying a ~20% annual shareholder return. By comparison, the potential would be ~210% (~25% annualised) assuming 26x '29e EV/EBIT, but -7% (-1% annualised) assuming 6x '29e EV/EBIT.

2029 valuation scenario

Financial overview	Actual						ABGSC official					CAGR		
SEKm	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	'19-'25e	'19-'29e	'24-'27e
OEM	167	83	25	20	36	40	56	130	201	252	269	-17%	5%	71%
AM	147	72	99	187	243	233	176	218	275	316	363	3%	9%	6%
VIP	15	32	10	21	18	14	34	55	80	124	142	15%	25%	77%
Retrofit/other	27	14	18	13	13	12	18	24	27	31	37	-6%	3%	31%
Sales	355	201	151	241	309	300	285	427	583	722	812	-4%	9%	25%
y-o-y	13%	-43%	-25%	59%	28%	-3%	-5%	50%	36%	24%	12%			
Organic	7%	-42%	-19%	36%	23%	-2%	3%	54%	36%	24%	12%	-4%	9%	29%
AM % of sales	41%	36%	65%	78%	79%	78%	62%	51%	47%	44%	45%			
EBIT	120	38	27	92	118	112	53	126	186	236	269	-13%	8%	18%
Margin	34%	19%	18%	38%	38%	37%	19%	30%	32%	33%	33%			
y-o-y		-68%	-30%	243%	29%	-5%	-52%	136%	47%	27%	14%			
FCF	86	-44	22	54	109	62	60	86	113	158	189			
FCF conversion (FCF / EBIT)	72%	-116%	81%	59%	92%	55%	112%	68%	61%	67%	70%			
Dividends	-51	-51	-22	-10	-51	-109	-67	-75	-113	-150	-188			
% of EBIT -1y	n.a.	42%	57%	37%	55%	92%	60%	141%	89%	81%	79%			
ROIC	55%	13%	7%	30%	39%	35%	17%	40%	52%	59%	61%			
Market cap	2,215	1,907	2,713	2,675	2,869	3,521	2,418	2,418	2,418	2,418	2,418			
Net debt	-42	-42	-42	-42	-42	-42	-42	-42	-42	-42	-42			
Enterprise value	2,173	1,864	2,670	2,633	2,827	3,478	2,376	2,376	2,376	2,376	2,376			
EV/EBIT	18x	49x	100x	29x	24x	31x	44x	19x	13x	10x	9x			
EV/ AM EBIT (50% margins)	30x	52x	54x	28x	23x	30x	27x	22x	17x	15x	13x			
FCF yield	4%	-2%	1%	2%	4%	2%	2%	4%	5%	7%	8%			
Valuation scenario														
EV/EBIT 2029e	6x	8x	10x	12x	14x	16x	18x	20x	22x	24x	26x			
EV	1,611	2,148	2,685	3,222	3,759	4,297	4,834	5,371	5,908	6,445	6,982			
Net debt	-42	-42	-42	-42	-42	-42	-42	-42	-42	-42	-42			
Market cap	1,654	2,191	2,728	3,265	3,802	4,339	4,876	5,413	5,950	6,487	7,024			
Incl. dividends '25e-'29e	593	514	514	514	514	514	514	514	514	514	514			
Mcap, div adjusted	2,247	2,705	3,242	3,779	4,316	4,853	5,390	5,927	6,464	7,001	7,539			
Implied share price	179	216	259	302	344	387	430	473	516	559	602			
Annualised return	-1%	2%	6%	9%	12%	15%	17%	20%	22%	24%	26%			


Source: ABG Sundal Collier, company data

Return to operational outperformance vs. peers in 2026e

Because CTT operates in the aerospace industry, one could argue that the company should be compared to peers in the same industry. However, we believe that this downplays CTT's monopolistic (albeit with some competition risk from 'copy cats' of inferior quality) market position, as well as its operating and financial characteristics. In fact, one could make the case that the company is actually more closely related to companies in the medical technology (medtech) or Nordic technology (Nordic) sectors.


Similar to these peer groups, CTT has a strong, market-leading position, a high degree of recurring revenues (aftermarket, consumables or software) and high earnings growth, supported by high margins and a high return on capital. As shown below, CTT outperformed all peer groups in terms of EBIT growth until 2019, and was above medtech and aerospace in terms of sales growth. Following COVID-related challenges in the aerospace industry, and recent supply chain difficulties, that outperformance vs. peers has disappeared, but we expect the outperformance to return again in 2026e.

Indexed sales vs. peers



Source: ABG Sundal Collier, company data, FactSet


Indexed EBIT vs. peers



Source: ABG Sundal Collier, company data, FactSet


Looking ahead and compared to FactSet/ABGSC estimates (see next page for more detailed numbers), we find that CTT is trading above peers on an EV/EBIT basis for 2025e, in line with peers on 2026e EV/EBIT, but below all peers for 2027e. In addition, the current F12m PE stands at ~27x (using ABGSC F12m EPS), which is 8% below the 5-year average.

EV/EBIT vs. selected peer groups



Source: ABG Sundal Collier, company data, FactSet

P/E F12m valuation vs. 5Y avg.



Source: ABG Sundal Collier, FactSet

Peer overview

Valuation	Mcap SEKm	EV/Sales			EV/EBIT			P/E			ROCE (%)			DY (%)
		2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e	2025e	2026e	2027e	2025e
Aerospace peers														
Boeing	1,573,330	2.30	2.00	1.70	119.2	32.6	20.9	n.a.	68.3	34.5	3.1	11.4	16.6	0.0
Airbus	1,804,849	2.05	1.80	1.57	21.6	17.9	14.7	32.2	26.3	22.0	10.7	11.8	13.1	1.3
United Technologies	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Honeywell	1,289,910	3.92	3.95	3.70	16.8	16.5	15.2	20.3	20.1	18.5	16.7	17.0	18.2	2.1
Moog Inc	6,582	1.96	1.81	n.a.	16.9	14.5	n.a.	25.0	21.5	n.a.	12.7	13.4	n.a.	0.5
Spirit Aerosystems	43,576	1.18	1.03	0.87	n.a.	16.4	11.1	n.a.	46.7	14.6	-49.1	n.a.	n.a.	0.0
Safran	1,409,726	4.06	3.56	3.21	24.4	20.7	18.0	36.8	28.5	25.0	28.2	30.1	31.3	1.1
Thales	570,308	2.47	2.26	2.04	20.3	17.7	15.6	27.1	23.1	20.6	17.2	18.4	18.0	1.5
Aero median	1,289,910	2.30	2.00	1.87	20.9	17.7	15.4	27.1	26.3	21.3	12.7	15.2	18.0	1.1
Medtech peers														
Biotage	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Boule Diagnostics	204	0.73	0.62	0.53	8.0	5.9	4.8	8.9	5.9	4.9	n.a.	n.a.	n.a.	0.0
Cellavision	4,494	5.64	4.97	4.37	22.2	17.9	15.1	28.0	23.0	19.5	20.0	21.0	21.5	1.5
Elekta	18,429	1.32	1.28	1.20	13.8	11.0	9.7	14.8	13.3	11.7	10.1	12.4	13.3	4.7
Ossur	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Raysearch	6,627	5.91	5.16	4.29	29.6	20.4	15.0	41.1	28.5	21.8	18.1	24.1	28.1	1.3
Sectra	56,353	17.25	14.97	12.78	90.7	72.0	55.7	111.5	90.2	66.0	30.0	32.8	33.2	0.5
Vitrolife	20,466	6.05	5.55	4.94	31.2	24.4	20.7	36.0	29.2	25.5	4.0	4.9	5.5	0.6
Medtech median	12,528	5.77	5.06	4.33	25.9	19.2	15.1	32.0	25.8	20.6	18.1	21.0	21.5	1.0
Nordic peers														
Evolution Gaming	137,767	5.76	5.28	4.72	9.9	9.0	8.0	12.1	11.0	9.8	27.6	27.1	26.9	4.3
Hexagon	313,633	6.05	5.67	5.24	24.2	19.7	18.5	27.6	25.0	22.1	9.2	10.5	10.7	1.2
HMS Networks	25,637	7.91	6.84	6.05	35.0	28.8	24.5	42.2	34.9	29.8	12.7	14.5	15.9	0.6
I.A.R Systems	2,348	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	33.3	33.9	33.3	n.a.	n.a.	n.a.	0.8
MIPS	9,834	17.28	12.88	9.86	56.5	30.1	21.4	67.6	38.6	27.6	27.6	46.0	54.0	1.8
Mycronic	42,525	5.15	4.93	4.76	20.2	19.2	18.9	23.9	25.0	25.2	25.1	23.2	21.1	2.2
Nordic median	34,081	6.05	5.67	5.24	24.2	19.7	18.9	30.5	29.5	26.4	25.1	23.2	21.1	1.5
Peer group avg	386,137	5.39	4.70	4.23	33.0	21.9	18.1	34.6	31.2	24.0	13.2	19.9	21.8	1.4
CTT Systems*	2,869	8.41	5.58	4.09	44.8	18.9	12.8	55.1	23.4	16.0	17.3	40.1	54.4	3.1
vs. Aero peers		266%	179%	119%	114%	7%	-16%	103%	-11%	-25%	4.7	24.9	36.3	2.0
vs. Medtech peers		46%	10%	-6%	73%	-1%	-15%	72%	-9%	-23%	-0.7	19.1	32.9	2.2
vs. Nordic peers		39%	-2%	-22%	85%	-4%	-32%	81%	-21%	-39%	-7.8	16.9	33.3	1.6
vs. total peer group		56%	19%	-3%	36%	-14%	-29%	59%	-25%	-33%	4.2	20.2	32.6	1.7
Performance	Mcap SEKm	Gross margin (%)			EBIT margin (%)			Sales CAGR (%)			EBIT CAGR (%)			ND/EBITD.
		2025e	2026e	2027e	2025e	2026e	2027e	'18-'23	'20-'23	'23-'26e	'18-'23	'20-'23	'23-'26e	2025e
Aerospace peers														
Boeing	1,573,330	9.8	16.6	17.3	1.9	6.1	8.1	-5.1	10.2	7.5	-158.6	-49.4	-294.0	8.8
Airbus	1,804,849	16.3	16.9	17.2	9.5	10.0	10.7	0.5	9.5	8.3	6.4	85.9	25.1	-1.2
United Technologies	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Honeywell	1,289,910	35.7	36.3	37.4	23.4	23.9	24.4	-2.6	3.9	3.2	0.2	7.8	6.9	2.2
Moog Inc	6,582	27.6	27.8	27.8	11.4	12.3	13.1	4.1	4.8	6.5	3.0	6.9	16.3	1.6
Spirit Aerosystems	43,576	-2.1	n.a.	n.a.	-11.0	6.3	7.9	-3.5	21.1	11.9	-168.3	-42.0	-261.2	n.a.
Safran	1,409,726	35.3	35.1	35.4	16.7	17.2	17.8	2.4	12.5	14.1	7.3	32.9	32.4	-0.3
Thales	570,308	26.4	26.3	26.6	12.2	12.7	13.1	3.1	6.2	8.5	2.6	22.5	21.8	0.6
Aero median	1,289,910	26.4	27.1	27.2	11.4	12.3	13.1	0.5	9.5	8.3	2.6	7.8	16.3	1.1
Medtech peers														
Biotage	n.a.	n.a.	n.a.	n.a.	17.0	19.5	20.6	15.4	19.5	5.3	17.3	19.7	4.1	-0.7
Boule Diagnostics	204	42.4	43.0	43.6	9.1	10.5	11.1	6.1	12.6	-2.2	-3.3	-236.9	9.1	4.0
Cellavision	4,494	68.8	69.6	70.2	25.4	27.7	29.0	13.2	12.8	8.3	8.4	14.8	12.5	0.7
Elekta	18,429	37.7	38.3	38.8	11.2	11.9	12.5	6.0	9.6	0.5	6.1	7.6	-2.5	-1.3
Ossur	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Raysearch	6,627	91.6	91.5	91.3	19.9	25.3	28.5	10.3	16.2	13.0	11.6	67.3	45.8	-0.5
Sectra	56,353	86.3	86.7	86.6	19.0	21.5	23.5	16.0	22.0	11.8	17.4	14.0	19.8	-1.7
Vitrolife	20,466	59.0	59.6	59.9	19.4	22.7	23.9	25.0	41.3	1.4	12.6	26.2	4.4	0.5
Medtech median	12,528	63.9	64.6	65.1	19.0	21.5	23.5	13.2	16.2	5.3	11.6	14.8	9.1	-0.5
Nordic peers														
Evolution Gaming	137,767	95.9	95.3	95.2	58.5	58.5	58.8	52.3	52.0	5.8	70.2	57.6	3.0	-0.4
Hexagon	313,633	66.4	66.2	67.2	25.0	28.8	28.3	10.1	16.4	-0.4	14.9	20.8	-1.8	1.6
HMS Networks	25,637	63.3	64.6	65.0	22.6	23.8	24.7	17.2	27.3	9.9	25.5	37.5	7.1	2.3
I.A.R Systems	2,348	n.a.	n.a.	n.a.	18.8	19.0	18.6	3.5	7.2	0.8	-5.7	0.9	1.1	n.a.
MIPS	9,834	73.3	73.2	73.5	30.6	42.8	46.2	13.1	-0.7	27.3	0.9	-21.1	54.8	-1.7
Mycronic	42,525	53.2	53.0	51.6	25.6	25.6	25.2	8.5	13.7	11.9	2.7	7.2	19.9	-1.0
Nordic median	34,081	66.4	66.2	67.2	25.3	27.2	26.8	11.6	15.0	7.9	8.8	14.0	5.0	-0.4
Peer group avg	386,137	49.3	53.0	53.2	18.3	21.3	22.3	9.8	15.9	7.7	-6.4	4.0	-13.8	0.8
CTT Systems*	2,869				18.8	29.5	31.9	-3.3	15.4	24.7	0.0	56.3	18.2	-0.2
vs. Aero peers					7.4	17.2	18.8	-3.8	6.0	16.4	-2.7	48.5	1.9	-1.3
vs. Medtech peers					-0.2	8.0	8.4	-16.5	-0.8	19.4	-11.6	41.4	9.1	0.3
vs. Nordic peers					-6.5	2.3	5.1	-14.9	0.4	16.9	-8.9	42.3	13.2	0.2
vs. total peer group					0.5	8.2	9.6	-13.1	-0.5	17.1	6.4	52.3	32.0	-1.0

*ABGSC estimates, adjusted for NRI and PPA amortisation

Source: ABG Sundal Collier, company data, FactSet

Quarterly overview

Quarterly overview (€)	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25e
Net sales	49	58	65	68	75	79	74	81	78	82	57	82	54	80	74	77
Other income	5	7	6	4	-5	6	1	2	7	8	-2	5	7	5	6	7
Opex	-39	-40	-36	-49	-44	-49	-42	-49	-50	-57	-39	-52	-55	-66	-60	-69
EBITDA	16	25	35	23	26	36	33	34	35	33	17	35	6	20	20	15
D&A	-2	-2	-2	-2	-3	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2	-2
EBIT	14	23	33	21	23	34	31	32	33	31	15	34	4	18	19	13
Non-recurring items	0	0	0	0	-3	0	0	0	0	0	0	0	0	-2	0	0
Adj. EBIT	14	23	33	21	26	34	31	32	33	31	15	34	4	20	19	13
Net fin expenses	-2	-4	-3	2	0	-3	1	3	-2	0	0	-3	1	1	0	1
PTP	12	19	30	23	23	31	32	35	31	31	15	30	5	19	18	14
Taxes	-2	-4	-6	-5	-5	-6	-7	-7	-6	-6	-3	-6	-1	-4	-4	-3
Net profit	10	15	24	18	18	25	25	27	25	25	12	24	4	15	14	11
Metrics	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25e
EBIT margin	28%	40%	51%	31%	30%	43%	41%	39%	42%	38%	26%	41%	7%	23%	25%	17%
Adj. EBIT margin	28%	40%	51%	31%	34%	43%	41%	39%	42%	38%	26%	41%	7%	25%	25%	17%
Net profit margin	19%	26%	37%	26%	24%	31%	34%	34%	31%	30%	21%	29%	7%	19%	20%	14%
Tax rate	20%	20%	21%	22%	21%	21%	21%	21%	21%	21%	21%	21%	21%	21%	20%	21%
Sales y-o-y	57%	56%	62%	61%	52%	35%	13%	20%	4%	4%	-22%	1%	-31%	-3%	29%	-6%
Organic	42%	36%	34%	33%	36%	27%	10%	21%	5%	3%	-18%	1%	-33%	7%	39%	7%
FX	15%	20%	28%	28%	16%	8%	3%	-1%	-1%	1%	-4%	0%	2%	-10%	-10%	-13%
Adj. EBIT y-o-y	2233%	1188%	191%	160%	82%	44%	-9%	52%	28%	-7%	-51%	6%	-88%	-36%	25%	-61%
EBIT y-o-y	2233%	254%	191%	160%	61%	44%	-9%	52%	44%	-7%	-51%	6%	-88%	-43%	25%	-61%
Sales breakdown	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25e
OEM	7	6	3	4	13	8	6	8	10	10	10	10	18	10	12	17
Retrofits	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	3
VIP	3	9	4	6	7	1	9	2	3	2	1	8	1	10	13	10
Other	3	3	3	4	3	4	3	3	3	4	3	3	4	3	3	3
System sales	13	18	9	14	23	14	17	13	16	16	14	21	23	23	30	33
Aftermarket	37	40	56	54	52	66	57	68	63	66	43	61	32	57	44	44
IP	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Group sales	49	58	65	68	75	79	74	81	78	82	57	82	54	80	74	77

Source: ABG Sundal Collier, company data

Annual overview

Annual overview (SEKm)	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Net sales	152	150	195	198	252	273	315	355	201	151	241	309	300	285	427	583
Other income	7	16	10	14	3	4	21	22	32	25	23	3	19	25	24	22
Opex	-138	-150	-185	-173	-192	-212	-240	-250	-188	-138	-164	-184	-199	-249	-318	-408
EBITDA	21	17	20	39	63	66	96	126	45	38	100	128	120	60	134	197
Depreciation & amortisation	-8	-10	-15	-10	-12	-8	-6	-7	-7	-11	-8	-9	-8	-7	-8	-11
EBIT	14	7	6	29	51	58	90	120	38	27	92	118	112	53	126	186
Non-recurring items	0	0	0	0	-1	0	-2	7	7	5	0	-3	0	-2	0	0
Adj. EBIT	14	7	6	29	52	58	92	113	32	22	92	121	112	55	126	186
Net financial expenses	0	-2	-4	-3	-2	3	-1	-2	1	-9	-8	2	-5	2	4	5
PTP	14	5	2	26	48	61	89	118	40	18	84	120	108	55	130	191
Taxes	-10	-1	-1	-6	-11	-14	-20	-25	-9	-4	-17	-25	-22	-11	-27	-39
Net profit	3	4	1	20	38	48	70	93	31	14	66	96	85	44	103	151
Metrics	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBIT margin	9%	4%	3%	15%	20%	21%	29%	34%	19%	18%	38%	38%	37%	19%	30%	32%
Adj. EBIT margin	9%	4%	3%	15%	21%	21%	29%	32%	16%	14%	38%	39%	37%	19%	30%	32%
Net profit margin	2%	3%	1%	10%	15%	17%	22%	26%	16%	9%	28%	31%	28%	15%	24%	26%
Tax rate	76%	21%	29%	22%	22%	22%	22%	21%	21%	21%	21%	21%	21%	21%	21%	21%
Sales y-o-y	52%	-1%	30%	2%	27%	9%	15%	13%	-43%	-25%	59%	28%	-3%	-5%	50%	36%
Organic	52%	-4%	24%	-17%	26%	10%	13%	5%	-44%	-19%	36%	23%	-2%	3%	54%	36%
FX	0%	2%	6%	19%	1%	-2%	2%	8%	0%	-5%	23%	6%	-1%	-8%	-4%	0%
Adj. EBIT y-o-y	-494%	-51%	-16%	420%	78%	12%	60%	22%	-72%	-31%	318%	32%	-7%	-51%	128%	47%
EBIT y-o-y	-494%	-51%	-16%	420%	74%	14%	56%	33%	-68%	-30%	243%	29%	-5%	-52%	136%	47%
Sales breakdown	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
OEM				111	109	104	126	167	83	25	20	36	40	56	130	201
Retrofits				13	14	35	30	10	5	8	0	0	0	6	12	14
VIP				24	28	15	14	15	32	10	21	18	14	34	55	80
Other				8	15	21	22	17	9	11	13	13	12	13	13	13
System sales				156	166	175	192	208	129	53	54	66	67	109	209	308
Aftermarket				35	54	78	102	136	72	99	187	243	233	176	218	275
IP				7	32	21	22	11	0	0	0	0	0	0	0	0
Group sales	152	150	195	198	252	273	315	355	201	151	241	309	300	285	427	583
y-o-y				2%	27%	9%	15%	13%	-43%	-25%	59%	28%	-3%	-5%	50%	36%
Sales breakdown %	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
OEM				56%	43%	38%	40%	47%	41%	16%	8%	11%	13%	20%	30%	35%
Retrofits				7%	5%	13%	9%	3%	2%	5%	0%	0%	0%	2%	3%	2%
VIP				12%	11%	5%	4%	4%	16%	6%	9%	6%	5%	12%	13%	14%
Other				4%	6%	8%	7%	5%	5%	7%	5%	4%	4%	4%	3%	2%
System sales				79%	66%	64%	61%	59%	64%	35%	22%	21%	22%	38%	49%	53%
Aftermarket				18%	21%	28%	32%	38%	36%	65%	78%	79%	78%	62%	51%	47%
IP				4%	13%	8%	7%	3%	0%	0%	0%	0%	0%	0%	0%	0%
AM+IP / sales			0%	21%	34%	36%	39%	41%	36%	65%	78%	79%	78%	62%	51%	47%
Other metrics	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ND/EBITDA	2.3	4.9	2.0	0.9	0.2	-0.5	-0.4	-0.6	0.3	0.6	0.0	-0.2	-0.2	-0.4	-0.2	-0.2
NWC / sales	23%	35%	26%	32%	30%	24%	26%	20%	56%	75%	55%	38%	49%	46%	34%	30%
ROE	5%	6%	1%	19%	30%	31%	39%	42%	14%	7%	28%	33%	28%	16%	37%	48%
ROIC	3%	4%	3%	16%	27%	32%	50%	55%	13%	7%	30%	39%	35%	17%	40%	52%
ROCE	12%	5%	3%	17%	28%	31%	44%	45%	12%	8%	31%	36%	33%	17%	40%	54%

Source: ABG Sundal Collier, company data

Income Statement (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	315	355	201	151	241	309	300	285	427	583
COGS	0	0	0	0	0	0	0	0	0	0
Gross profit	315	355	201	151	241	309	300	285	427	583
Other operating items	-219	-229	-156	-113	-141	-181	-180	-225	-294	-386
EBITDA	96	126	45	38	100	128	120	60	134	197
Depreciation and amortisation	-6	-7	-7	-11	-8	-9	-8	-7	-8	-11
of which leasing depreciation	0	0	0	0	0	0	0	0	0	0
EBITA	90	120	38	27	92	118	112	53	126	186
EO Items	-2	7	7	5	0	-3	0	-2	0	0
Impairment and PPA amortisation	0	0	0	0	0	0	0	0	0	0
EBIT	90	120	38	27	92	118	112	53	126	186
Net financial items	-1	-2	1	-9	-8	2	-5	2	4	5
Pretax profit	89	118	40	18	84	120	108	55	130	191
Tax	-20	-25	-9	-4	-17	-25	-22	-11	-27	-39
Net profit	70	93	31	14	66	96	85	44	103	151
Minority interest	0	0	0	0	0	0	0	0	0	0
Net profit discontinued	0	0	0	0	0	0	0	0	0	0
Net profit to shareholders	70	93	31	14	66	96	85	44	103	151
EPS	5.56	7.39	2.49	1.13	5.30	7.62	6.81	3.50	8.25	12.08
EPS adj.	5.70	6.96	2.07	0.82	5.30	7.81	6.81	3.63	8.25	12.08
Total extraordinary items after tax	-2	5	5	4	0	-2	0	-2	0	0
Leasing payments	0	0	0	0	0	0	0	0	0	0
<i>Tax rate (%)</i>	<i>22.1</i>	<i>21.5</i>	<i>21.4</i>	<i>20.8</i>	<i>20.8</i>	<i>20.7</i>	<i>20.7</i>	<i>20.7</i>	<i>20.6</i>	<i>20.6</i>
<i>Gross margin (%)</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>	<i>100.0</i>
<i>EBITDA margin (%)</i>	<i>30.5</i>	<i>35.6</i>	<i>22.5</i>	<i>25.1</i>	<i>41.4</i>	<i>41.3</i>	<i>40.0</i>	<i>21.1</i>	<i>31.3</i>	<i>33.8</i>
<i>EBITA margin (%)</i>	<i>28.6</i>	<i>33.7</i>	<i>19.1</i>	<i>17.7</i>	<i>38.1</i>	<i>38.3</i>	<i>37.5</i>	<i>18.8</i>	<i>29.5</i>	<i>31.9</i>
<i>EBIT margin (%)</i>	<i>28.6</i>	<i>33.7</i>	<i>19.1</i>	<i>17.7</i>	<i>38.1</i>	<i>38.3</i>	<i>37.5</i>	<i>18.8</i>	<i>29.5</i>	<i>31.9</i>
<i>Pre-tax margin (%)</i>	<i>28.4</i>	<i>33.2</i>	<i>19.7</i>	<i>11.8</i>	<i>34.8</i>	<i>39.0</i>	<i>35.8</i>	<i>19.4</i>	<i>30.5</i>	<i>32.7</i>
<i>Net margin (%)</i>	<i>22.1</i>	<i>26.1</i>	<i>15.5</i>	<i>9.3</i>	<i>27.6</i>	<i>30.9</i>	<i>28.4</i>	<i>15.4</i>	<i>24.2</i>	<i>26.0</i>
Growth Rates y-o-y	-	-	-	-	-	-	-	-	-	-
<i>Sales growth (%)</i>	<i>15.4</i>	<i>12.5</i>	<i>-43.4</i>	<i>-24.7</i>	<i>59.2</i>	<i>28.3</i>	<i>-2.8</i>	<i>-5.1</i>	<i>50.0</i>	<i>36.4</i>
<i>EBITDA growth (%)</i>	<i>46.8</i>	<i>31.2</i>	<i>-64.2</i>	<i>-16.0</i>	<i>162.3</i>	<i>28.1</i>	<i>-5.9</i>	<i>-50.0</i>	<i>122.6</i>	<i>47.1</i>
<i>EBITA growth (%)</i>	<i>55.6</i>	<i>32.6</i>	<i>-67.9</i>	<i>-30.4</i>	<i>243.2</i>	<i>29.1</i>	<i>-5.0</i>	<i>-52.5</i>	<i>136.0</i>	<i>47.1</i>
<i>EBIT growth (%)</i>	<i>55.6</i>	<i>32.6</i>	<i>-67.9</i>	<i>-30.4</i>	<i>nm</i>	<i>29.1</i>	<i>-5.0</i>	<i>-52.5</i>	<i>nm</i>	<i>47.1</i>
<i>Net profit growth (%)</i>	<i>46.5</i>	<i>32.9</i>	<i>-66.4</i>	<i>-54.7</i>	<i>369.9</i>	<i>43.9</i>	<i>-10.7</i>	<i>-48.5</i>	<i>135.5</i>	<i>46.4</i>
<i>EPS growth (%)</i>	<i>46.5</i>	<i>32.9</i>	<i>-66.4</i>	<i>-54.7</i>	<i>nm</i>	<i>43.9</i>	<i>-10.7</i>	<i>-48.5</i>	<i>nm</i>	<i>46.4</i>
Profitability	-	-	-	-	-	-	-	-	-	-
<i>ROE (%)</i>	<i>38.6</i>	<i>42.2</i>	<i>13.5</i>	<i>6.5</i>	<i>27.5</i>	<i>32.7</i>	<i>28.2</i>	<i>15.7</i>	<i>36.7</i>	<i>48.1</i>
<i>ROE adj. (%)</i>	<i>39.5</i>	<i>39.8</i>	<i>11.3</i>	<i>4.8</i>	<i>27.5</i>	<i>33.5</i>	<i>28.2</i>	<i>16.3</i>	<i>36.7</i>	<i>48.1</i>
<i>ROCE (%)</i>	<i>42.8</i>	<i>47.6</i>	<i>15.4</i>	<i>9.9</i>	<i>30.6</i>	<i>36.5</i>	<i>32.6</i>	<i>17.9</i>	<i>42.6</i>	<i>57.3</i>
<i>ROCE adj. (%)</i>	<i>43.9</i>	<i>44.8</i>	<i>12.0</i>	<i>8.1</i>	<i>30.6</i>	<i>36.2</i>	<i>32.6</i>	<i>17.3</i>	<i>40.1</i>	<i>54.4</i>
<i>ROIC (%)</i>	<i>48.5</i>	<i>58.0</i>	<i>15.1</i>	<i>9.0</i>	<i>29.6</i>	<i>38.1</i>	<i>35.4</i>	<i>16.6</i>	<i>39.5</i>	<i>52.4</i>
<i>ROIC adj. (%)</i>	<i>49.8</i>	<i>54.6</i>	<i>12.5</i>	<i>7.4</i>	<i>29.6</i>	<i>39.1</i>	<i>35.4</i>	<i>17.2</i>	<i>39.5</i>	<i>52.4</i>
Adj. earnings numbers	-	-	-	-	-	-	-	-	-	-
EBITDA adj.	99	119	39	33	100	131	120	62	134	197
<i>EBITDA adj. margin (%)</i>	<i>31.2</i>	<i>33.6</i>	<i>19.2</i>	<i>21.9</i>	<i>41.4</i>	<i>42.2</i>	<i>40.0</i>	<i>21.8</i>	<i>31.3</i>	<i>33.8</i>
EBITDA lease adj.	99	119	39	33	100	131	120	62	134	197
<i>EBITDA lease adj. margin (%)</i>	<i>31.2</i>	<i>33.6</i>	<i>19.2</i>	<i>21.9</i>	<i>41.4</i>	<i>42.2</i>	<i>40.0</i>	<i>21.8</i>	<i>31.3</i>	<i>33.8</i>
EBITA adj.	92	113	32	22	92	121	112	55	126	186
<i>EBITA adj. margin (%)</i>	<i>29.3</i>	<i>31.7</i>	<i>15.8</i>	<i>14.5</i>	<i>38.1</i>	<i>39.3</i>	<i>37.5</i>	<i>19.5</i>	<i>29.5</i>	<i>31.9</i>
EBIT adj.	92	113	32	22	92	121	112	55	126	186
<i>EBIT adj. margin (%)</i>	<i>29.3</i>	<i>31.7</i>	<i>15.8</i>	<i>14.5</i>	<i>38.1</i>	<i>39.3</i>	<i>37.5</i>	<i>19.5</i>	<i>29.5</i>	<i>31.9</i>
Pretax profit Adj.	92	111	33	13	84	123	108	57	130	191
Net profit Adj.	71	87	26	10	66	98	85	45	103	151
Net profit to shareholders adj.	71	87	26	10	66	98	85	45	103	151
<i>Net adj. margin (%)</i>	<i>22.7</i>	<i>24.6</i>	<i>12.9</i>	<i>6.8</i>	<i>27.6</i>	<i>31.7</i>	<i>28.4</i>	<i>16.0</i>	<i>24.2</i>	<i>26.0</i>

Source: ABG Sundal Collier, Company Data

Cash Flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	96	126	45	38	100	128	120	60	134	197
Net financial items	-1	-2	1	-9	-8	2	-5	2	4	5
Paid tax	-9	-14	-35	-7	-13	-33	-29	-11	-27	-39
Non-cash items	0	-3	-11	6	7	-4	3	-2	0	0
Cash flow before change in WC	86	108	0	28	85	93	89	49	111	162
Change in working capital	-25	0	-11	3	-24	24	-23	15	-12	-32

Cash Flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Operating cash flow	61	109	-11	30	61	117	66	64	99	131
Capex tangible fixed assets	-5	-9	-13	-0	-2	-3	-2	-2	-4	-6
Capex intangible fixed assets	-20	-14	-21	-8	-5	-4	-2	-2	-9	-12
Acquisitions and Disposals	0	5	0	0	-0	-0	0	0	0	0
Free cash flow	37	91	-44	22	54	109	62	60	86	113
Dividend paid	-35	-51	-51	-22	-10	-51	-109	-67	-75	-113
Share issues and buybacks	0	0	0	0	0	0	0	0	0	0
Leasing liability amortisation	0	0	0	0	0	0	0	0	0	0
Other non-cash items	0	-2	5	-5	-6	3	-3	4	0	0
Balance Sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Goodwill	0	0	0	0	0	0	0	0	0	0
Other intangible assets	43	55	73	76	80	81	81	79	84	90
Tangible fixed assets	41	45	54	48	43	41	39	36	35	36
Right-of-use asset	0	0	0	0	0	0	0	0	0	0
Total other fixed assets	2	2	2	2	2	2	2	2	2	2
Fixed assets	86	102	129	126	125	124	121	116	121	128
Inventories	81	73	101	100	116	109	125	114	137	163
Receivables	84	78	56	53	75	67	78	74	94	131
Other current assets	0	0	0	0	0	0	0	0	0	0
Cash and liquid assets	69	110	22	49	60	118	69	60	62	58
Total assets	319	363	308	329	377	417	393	364	414	480
Shareholders equity	198	240	221	213	269	314	291	267	296	334
Minority	0	0	0	0	0	0	0	0	0	0
Total equity	198	240	221	213	269	314	291	267	296	334
Long-term debt	31	33	36	71	44	40	43	37	29	24
Pension debt	0	0	0	0	0	0	0	0	0	0
Convertible debt	0	0	0	0	0	0	0	0	0	0
Leasing liability	0	0	0	0	0	0	0	0	0	0
Total other long-term liabilities	7	8	6	4	3	3	1	2	2	2
Short-term debt	0	0	1	1	2	2	2	1	0	0
Accounts payable	83	82	44	40	59	59	57	57	88	119
Other current liabilities	0	0	0	0	0	0	0	0	0	0
Total liabilities and equity	319	363	308	329	377	417	393	364	414	480
Net IB debt	-37	-78	15	23	-15	-76	-25	-22	-33	-34
Net IB debt excl. pension debt	-37	-78	15	23	-15	-76	-25	-22	-33	-34
Net IB debt excl. leasing	-37	-78	15	23	-15	-76	-25	-22	-33	-34
Capital employed	230	273	257	285	315	356	335	305	325	358
Capital invested	161	163	236	236	255	238	266	245	262	301
Working capital	82	69	113	114	133	117	146	131	143	175
EV breakdown	-	-	-	-	-	-	-	-	-	-
Market cap. diluted (m)	2,418	2,418	2,418	2,418	2,418	2,418	2,418	2,418	2,418	2,418
Net IB debt adj.	-37	-78	15	23	-15	-76	-25	-22	-33	-34
Market value of minority	0	0	0	0	0	0	0	0	0	0
EV	2,381	2,341	2,433	2,441	2,403	2,342	2,393	2,396	2,385	2,384
Total assets turnover (%)	108.6	104.1	59.9	47.5	68.2	77.8	74.1	75.2	109.7	130.3
Working capital/sales (%)	23.3	21.4	45.5	75.1	51.2	40.4	43.8	48.6	32.1	27.3
Financial risk and debt service	-	-	-	-	-	-	-	-	-	-
Net debt/equity (%)	-18.8	-32.3	6.9	10.8	-5.4	-24.2	-8.5	-8.4	-11.2	-10.1
Net debt / market cap (%)	-1.5	-3.2	0.6	0.9	-0.6	-3.1	-1.0	-0.9	-1.4	-1.4
Equity ratio (%)	62.2	66.2	71.7	64.8	71.4	75.2	73.9	73.4	71.3	69.7
Net IB debt adj. / equity (%)	-18.8	-32.3	6.9	10.8	-5.4	-24.2	-8.5	-8.4	-11.2	-10.1
Current ratio	2.83	3.19	3.96	4.94	4.16	4.88	4.62	4.26	3.34	2.95
EBITDA/net interest	137.5	78.9	36.1	4.3	12.6	62.2	24.3	32.3	33.4	39.3
Net IB debt/EBITDA (x)	-0.4	-0.6	0.3	0.6	-0.1	-0.6	-0.2	-0.4	-0.2	-0.2
Net IB debt/EBITDA lease adj. (x)	-0.4	-0.6	0.4	0.7	-0.1	-0.6	-0.2	-0.4	-0.2	-0.2
Interest coverage	128.8	74.7	30.7	3.0	11.6	57.8	22.7	28.7	31.6	37.1

Source: ABG Sundal Collier, Company Data

Share Data (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Actual shares outstanding	13	13	13	13	13	13	13	13	13	13
Actual shares outstanding (avg)	13	13	13	13	13	13	13	13	13	13
Actual dividend per share	4.05	4.05	1.74	0.79	4.05	8.70	5.35	6.00	9.00	12.00
Reported earnings per share	5.56	7.39	2.49	1.13	5.30	7.62	6.81	3.50	8.25	12.08

Source: ABG Sundal Collier, Company Data

Valuation and Ratios (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Shares outstanding adj.	13	13	13	13	13	13	13	13	13	13
Diluted shares adj.	13	13	13	13	13	13	13	13	13	13
EPS	5.56	7.39	2.49	1.13	5.30	7.62	6.81	3.50	8.25	12.08
Dividend per share	4.05	4.05	1.74	0.79	4.05	8.70	5.35	6.00	9.00	12.00
EPS adj.	5.70	6.96	2.07	0.82	5.30	7.81	6.81	3.63	8.25	12.08
BVPS	15.83	19.17	17.60	16.99	21.49	25.06	23.19	21.34	23.59	26.68
BVPS adj.	12.39	14.82	11.77	10.93	15.09	18.62	16.75	15.06	16.87	19.47
Net IB debt/share	-2.97	-6.19	1.22	1.83	-1.17	-6.07	-1.96	-1.79	-2.65	-2.69
Share price	193.00	193.00	193.00	193.00	193.00	193.00	193.00	193.00	193.00	193.00
Market cap. (m)	2,418	2,418	2,418	2,418	2,418	2,418	2,418	2,418	2,418	2,418
Valuation	-	-	-	-	-	-	-	-	-	-
P/E (x)	34.7	26.1	77.7	nm	36.4	25.3	28.4	55.1	23.4	16.0
EV/sales (x)	7.5	6.6	12.1	16.1	10.0	7.6	8.0	8.4	5.6	4.1
EV/EBITDA (x)	24.7	18.5	53.9	64.3	24.1	18.4	19.9	39.9	17.8	12.1
EV/EBITA (x)	26.4	19.6	63.4	91.4	26.2	19.8	21.3	44.8	18.9	12.8
EV/EBIT (x)	26.4	19.6	63.4	91.4	26.2	19.8	21.3	44.8	18.9	12.8
Dividend yield (%)	2.1	2.1	0.9	0.4	2.1	4.5	2.8	3.1	4.7	6.2
FCF yield (%)	1.5	3.8	-1.8	0.9	2.2	4.5	2.6	2.5	3.6	4.7
Le. adj. FCF yld. (%)	1.5	3.8	-1.8	0.9	2.2	4.5	2.6	2.5	3.6	4.7
P/BVPS (x)	12.19	10.07	10.97	11.36	8.98	7.70	8.32	9.04	8.18	7.24
P/BVPS adj. (x)	15.58	13.02	16.39	17.65	12.79	10.36	11.53	12.81	11.44	9.91
P/E adj. (x)	33.8	27.7	nm	nm	36.4	24.7	28.4	53.2	23.4	16.0
EV/EBITDA adj. (x)	24.2	19.6	63.1	73.6	24.1	17.9	19.9	38.6	17.8	12.1
EV/EBITA adj. (x)	25.8	20.8	76.5	111.4	26.2	19.3	21.3	43.2	18.9	12.8
EV/EBIT adj. (x)	25.8	20.8	76.5	111.4	26.2	19.3	21.3	43.2	18.9	12.8
EV/CE (x)	10.4	8.6	9.5	8.6	7.6	6.6	7.2	7.8	7.3	6.7
Investment ratios	-	-	-	-	-	-	-	-	-	-
Capex/sales (%)	7.8	6.3	16.7	5.7	3.0	2.4	1.4	1.5	3.0	3.0
Capex/depreciation	4.0	3.3	4.9	0.8	0.9	0.8	0.6	0.6	1.7	1.6

Source: ABG Sundal Collier, Company Data

Analyst Certification

We, ABGSC Capital Goods Research, Karl Bokvist and Adrian Gilani, analyst(s) with ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited (hereinafter collectively referred to as "ABG Sundal Collier"), and the author(s) of this report, certify that notwithstanding the existence of any such potential conflicts of interests referred to below, the views expressed in this report accurately reflect my/our personal view about the companies and securities covered in this report. I/We further certify that I/We has/have not been, nor am/are or will be, receiving direct or indirect compensation related to the specific recommendations or views contained in this report.

This report is produced by ABG Sundal Collier, which may cover companies either in accordance with legal requirements designed to promote the independence of investment research ("independent research") or as commissioned research. Commissioned research is paid for by the subject company. As such, commissioned research is deemed to constitute an acceptable minor non-monetary benefit (i.e., not investment research) as defined in MiFID II.

Analyst valuation methods

ABG Sundal Collier analysts may publish valuation ranges for stocks covered under Company Sponsored Research. These valuation ranges rely on various valuation methods. One of the most frequently used methods is the valuation of a company by calculation of that company's discounted cash flow (DCF). Another valuation method is the analysis of a company's return on capital employed relative to its cost of capital. Finally, the analysts may analyse various valuation multiples (e.g. the P/E multiples and the EV/EBITDA multiples) relative to global industry peers. In special cases, particularly for property companies and investment companies, the ratio of price to net asset value is considered. Valuation ranges may be changed when earnings and cash flow forecasts are changed. They may also be changed when the underlying value of a company's assets changes (in the cases of investment companies, property companies or insurance companies) or when factors impacting the required rate of return change.

Expected updates

ABGSC has no fixed schedule for updating its research reports. Unless expressly stated otherwise, ABGSC expects (but does not undertake) to issue updates when considered necessary by the research department, for example following the publication of new figures or forecasts by a company or in the event of any material news on a company or its industry.

Important Company Specific Disclosure

The following disclosures relate to the relationship between ABG Sundal Collier and its affiliates and the companies covered by ABG Sundal Collier referred to in this research report.

Unless disclosed in this section, ABG Sundal Collier has no required regulatory disclosures to make in relation to an ownership position for the analyst(s) and members of the analyst's household, ownership by ABG Sundal Collier, ownership in ABG Sundal Collier by the company(ies) to whom the report(s) refer(s) to, market making, managed or co-managed public offerings, compensation for provision of certain services, directorship of the analyst, or a member of the analyst's household, or in relation to any contractual obligations to the issuance of this research report.

ABG Sundal Collier has undertaken a contractual obligation to issue this report and receives predetermined compensation from the company covered in this report.

ABG Sundal Collier is not aware of any other actual, material conflicts of interest of the analyst or ABG Sundal Collier of which the analyst knows or has reason to know at the time of the publication of this report.

Production of report: 10/26/2025 21:09.

All prices are as of market close on 24 October, 2025 unless otherwise noted.

Disclaimer

This report has been prepared by ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, ABG Sundal Collier AB and/or ABG Sundal Collier Limited and any of their directors, officers, representatives and employees (hereinafter collectively referred to as "ABG Sundal Collier"). This report is not a product of any other affiliated or associated companies of any of the above entities.

This report is provided solely for the information and use of professional investors, who are expected to make their own investment decisions without undue reliance on this report. The information contained herein does not apply to, and should not be relied upon by, retail clients. This report is for distribution only under such circumstances as may be permitted by applicable law. Research reports prepared by ABG Sundal Collier are for information purposes only. The recommendation(s) in this report is (are) has/ have no regard to specific investment objectives and the financial situation or needs of any specific recipient. ABG Sundal Collier and/or its affiliates accepts no liability whatsoever for any losses arising from any use of this report or its contents. This report is not to be used or considered as an offer to sell, or a solicitation of an offer to buy. The information herein has been obtained from, and any opinions herein are based upon, sources believed reliable, but ABG Sundal Collier and/or its affiliates make no representation as to its accuracy or completeness and it should not be relied upon as such. All opinions and estimates herein

reflect the judgment of ABG Sundal Collier on the date of this report and are subject to change without notice. Past performance is not indicative of future results.

The compensation of our research analysts is determined exclusively by research management and senior management, but not including investment banking management. Compensation is not based on specific investment banking revenues, however, it is determined from the profitability of the ABG Sundal Collier group, which includes earnings from investment banking operations and other business. Investors should assume that ABG Sundal Collier ASA, ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge and/or ABG Sundal Collier AB is seeking or will seek investment banking or other business relationships with the companies in this report.

The research analyst(s) responsible for the preparation of this report may interact with trading desk and sales personnel and other departments for the purpose of gathering, synthesizing and interpreting market information. From time to time, ABG Sundal Collier and/or its affiliates and any shareholders, directors, officers, or employees thereof may (I) have a position in, or otherwise be interested in, any securities directly or indirectly connected to the subject of this report, or (II) perform investment banking or other services for, or solicit investment banking or other services from, a company mentioned in this report. ABG Sundal Collier and/or its affiliates rely on information barriers to control the flow of information contained in one or more areas of ABG Sundal Collier, into other areas, units, groups or affiliates of ABG Sundal Collier.

Norway: ABG Sundal Collier ASA is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet)

Denmark: ABG Sundal Collier Denmark, filial af ABG Sundal Collier ASA, Norge, is regulated by the Financial Supervisory Authority of Norway (Finanstilsynet) and the Danish Financial Supervisory Authority (Finanstilsynet)

Sweden: ABG Sundal Collier AB is regulated by the Swedish Financial Supervisory Authority (Finansinspektionen)

UK: This report is a communication made, or approved for communication in the UK, by ABG Sundal Collier Limited, authorised and regulated by the Financial Conduct Authority in the conduct of its business.

US: This report is being distributed in the United States (U.S.) in accordance with FINRA Rule 1220 by ABG Sundal Collier Inc., an SEC registered broker-dealer and a FINRA/SIPC member which accepts responsibility for its content and its compliance with FINRA Rule 2241. Research reports distributed in the U.S. are intended solely for "major U.S. institutional investors," and "U.S. institutional investors" as defined under Rule 15a-6 of the Securities Exchange Act of 1934 and any related interpretive guidance and no-action letters issued by the Staff of the U.S. Securities and Exchange Commission ("SEC") collectively ("SEC Rule 15a-6"). Each major U.S. institutional investor and U.S. institutional investor that receives a copy of this research report, by its acceptance of such report, represents that it agrees that it will not distribute this research report to any other person. This communication is only intended for major U.S. institutional investors and U.S. institutional investors. Any person which is not a major U.S. institutional investor, or a U.S. institutional investor as covered by SEC Rule 15a-6 must not rely on this communication. The delivery of this research report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. Any major U.S. institutional investor or U.S. institutional investor receiving this report which wishes to effect transactions in any securities referred to herein should contact ABG Sundal Collier Inc., not its affiliates. Further information on the securities referred to herein may be obtained from ABG Sundal Collier Inc., on request.

Singapore: This report is distributed in Singapore by ABG Sundal Collier Pte. Ltd, which is not licensed under the Financial Advisors Act (Chapter 110 of Singapore). In Singapore, this report may only be distributed to institutional investors as defined in Section 4A(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) ("SFA"), and should not be circulated to any other person in Singapore.

Canada: This report is being distributed by ABG Sundal Collier ASA in Canada pursuant to section 8.25 of National Instrument 31-103 or an equivalent provision and has not been tailored to the needs of any specific investor in Canada. The information contained in this report is not, and under no circumstances is to be construed as, a prospectus, an advertisement, a public offering or an offer to sell the securities described herein, in Canada or any province or territory thereof. No securities commission or similar regulatory authority in Canada has reviewed or considered this report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Under no circumstances is this report to be construed as an offer to sell such securities or as a solicitation of an offer to buy such securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada may only be made in accordance with applicable securities laws and only by a dealer properly registered under such securities laws, or alternatively, pursuant to an applicable dealer registration exemption, in the Canadian jurisdiction in which such offer or sale is made.

This report may not be reproduced, distributed, or published by any recipient for any purpose whatsoever without the prior written express permission of ABG Sundal Collier.

Additional information available upon request. If reference is made in this report to other companies and ABG Sundal Collier provides research coverage for those companies, details regarding disclosures may be found on our website www.abgsc.com.

© Copyright 2025 ABG Sundal Collier ASA

Norway
Ruseløkkveien 26, 8th floor
0251 Oslo
Norway
Tel: +47 22 01 60 00
Fax: +47 22 01 60 60

Denmark
Forbindelsesvej 12,
2100 Copenhagen
Denmark
Tel: +45 35 46 61 00
Fax: +45 35 46 61 10

Sweden
Regeringsgatan 25, 8th floor
111 53 Stockholm
Sweden
Tel: +46 8 566 286 00
Fax: +46 8 566 286 01

United Kingdom
10 Paternoster Row, 5th floor
London EC4M 7EJ
UK
Tel: +44 20 7905 5600
Fax: +44 20 7905 5601

USA
140 Broadway, Suite 4604
New York, NY 10005
USA
Tel: +1 212 605 3800
Fax: +1 212 605 3801

Singapore
10 Collyer Quay
Ocean Financial Center
#40-07, Singapore 049315
Tel +65 6808 6082

Germany
Schillerstrasse 2, 5. OG
60313 Frankfurt
Germany
Tel +49 69 96 86 96 0
Fax +49 69 96 86 96 99

Switzerland
ABG Sundal Collier AG
Representative Office
Schwanenplatz 4
6004 Lucerne
Switzerland
Tel +41 79 502 33 39